Pharmacoeconomic review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
CADTH
Record ID 32014000786
English
Authors' recommendations:
The cost per course of treatment with ingenol mebutate ($383) is similar to that of imiquimod 5% depending on how it is dosed ($353 to $529), but considerably higher than that of 5-FU ($34). Whether ingenol mebutate will generate savings or incur additional costs if listed by public plans depends on how ingenol mebutate will be utilized.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0330_Picato_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Diterpenes
- Keratosis, Actinic
- Economics, Pharmaceutical
- Dermatologic Agents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.